MRNA Moderna Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
18:02
Sep 02
Sep 02
Short MRNA to $30 on platform mismatch.
Short MRNA because the market values it as a platform, but the science is priced for one tumor; the stock tripled on a single interim melanoma readout, supporting a $30 target with 80%+ downside.
HIGH
13:43
Sep 02
Sep 02
Adds MRNA short, 30% portfolio
Adds to existing MRNA short at $155, average $151, sizing to 30% of portfolio; biotech balance returning is the stated backdrop.
HIGH
13:14
Sep 02
Sep 02
Author critiques MRNA's melanoma market size estimate versus RVMD's economics.
Author critiques MRNA's melanoma market size estimate versus RVMD's economics, framing it as a factual comparison rather than a trade call.
LOW
05:09
Sep 02
Sep 02
Author concedes the bull case for MRNA's melanoma data and partnership but frames it.
Author concedes the bull case for MRNA's melanoma data and partnership but frames it as a crowded short setup without stating a position.
05:09
Sep 02
Sep 02
Author argues MRNA is mispriced higher due to an unearned platform extrapolation.
Author argues MRNA is mispriced higher due to an unearned platform extrapolation, citing weak biology, manufacturing, competitor failures, and collapsing base business while confirming a short position.
05:09
Sep 02
Sep 02
MRNA short continues; cover at double-digit prices
Continues short MRNA at ~$154 after a $36B value surge on undisclosed HR/CI/OS data; core view remains market overextrapolated an interim melanoma win into a validated scalable platform; plan cover at double digits.
MED
05:09
Sep 02
Sep 02
MRNA short target $30; overpriced melanoma-only science
Short MRNA at ~$154 targeting $30 (80% downside); market overextrapolated one melanoma interim win into an entire scalable oncology platform, ignoring biology, manufacturing limits, competitor failures, and declining base; cover incrementally into double digits.
MED
21:37
Sep 01
Sep 01
AI marriage with biotech accelerates drugs.
AI is enabling personalized drug development by analyzing genetic data and shortening candidate discovery timelines. This accelerates the AI-biotech convergence and supports pharma and biotech names tied to AI drug discovery, with Moderna among visible examples.
MED
15:37
Sep 01
Sep 01
Adds to MRNA short at $147
Author discloses adding to an existing short position in Moderna at $147, signaling maintained bearish conviction at current levels.
MED
10:00
Sep 01
Sep 01
Falling yields could ignite biotech rally
Biotech momentum is beginning to appear in names such as Moderna in the US and Hanmi Pharm in Korea. Park sees these biotech shares as leveraged to lower Treasury yields: if the 10-year Treasury yield falls, biotech and battery companies that previously struggled under financing costs could gain explosive upside.
MED
06:56
Sep 01
Sep 01
Falling Treasury yields may fuel biotech rally
US and Korean biotech names are beginning to stir, and biotech is viewed as a rate-sensitive area that has been constrained by funding costs. If the 10-year Treasury yield falls, Park expects biotech and battery stocks that previously could not rally to gain strong upside momentum.
MED
01:29
Sep 01
Sep 01
Personalized cancer vaccines are emerging
Personalized mRNA cancer vaccines are becoming a genuine new modality after Moderna/Merck's Phase 3 data; BioNTech/Roche's colorectal failure appears due to a cold tumor and no checkpoint combination rather than invalidating the platform, so the theme is worth tracking into further data and FDA submission.
MED
23:59
Aug 31
Aug 31
Moderna melanoma vaccine breakthrough can go higher.
Cramer says the heavily shorted melanoma vaccine developer Moderna produced the exact breakthrough bulls expected, working with Merck on a vaccine for people who have beaten melanoma once; he thinks the stock still has huge potential to go higher.
HIGH
23:50
Aug 31
Aug 31
Moderna largest new short position
Short Moderna as the largest new short position in a 70/30 portfolio, with plans to diversify shorts over the coming weeks.
MED
01:37
Aug 29
Aug 29
Moderna rally is regulatory capture.
Friedberg notes Moderna's market cap tripled from roughly $20B to $60B on the mRNA cancer immunotherapy readout, but he argues the underlying neo-antigen process is a decades-old, publicly funded technique and is already being done for about $50,000 in some clinics. He sees the $500,000 pricing, patents, and FDA monopoly as regulatory capture, expects cheap proliferation overseas, and is disappointed by the rally's setup.
MED
15:39
Aug 28
Aug 28
Moderna success narrative disputed on IMcode-004
Moderna's success narrative is disputed by the author, who cites IMcode-004 failure and says absence of negative evidence is not proof of concept; no directional trade view stated.
LOW
14:51
Aug 28
Aug 28
BNTX failure readthrough undermines MRNA cancer vaccine
Short MRNA because BNTX's similar neoantigen vaccine failed in colorectal adjuvant and other adjuvant settings, indicating MRNA's adjuvant melanoma proof-of-concept is a low bar unlikely to translate to other tumor types.
MED
13:53
Aug 28
Aug 28
Stay short MRNA
Maintain short MRNA exposure; the position remains short with no new catalyst restated in this update.
MED
13:24
Aug 28
Aug 28
Moderna and Merck shares decline after BioNTech halts its cancer vaccine trial.
Moderna and Merck shares decline after BioNTech halts its cancer vaccine trial, with Moderna having recently completed a convertible offering.
12:44
Aug 28
Aug 28
MRNA short call based on valuation
Speaker frames MRNA as a short at $160 purely on valuation, rejecting catalyst-based short framing; no deterioration mechanism or position disclosure stated.
MED
12:11
Aug 28
Aug 28
Short MRNA: aggressive note deal becomes debt.
Short MRNA: the upsized $2.6B note offering is aggressively priced and likely becomes debt that must be repaid unless MRNA reaches a Regeneron-like valuation by maturity, favoring short sellers.
MED
07:46
Aug 28
Aug 28
MRNA gets productivity boost from vertical AI
Buy MRNA because pre-existing vertical AI massively boosts biotech productivity, and its cancer vaccine was developed with bio vertical AI, giving Moderna an AI tailwind independent of generative AI platforms.
MED
03:59
Aug 28
Aug 28
Author argues AI boosts biotech innovation via specialized tools rather than general models.
Author argues AI boosts biotech innovation via specialized tools rather than general models, citing MRNA as evidence while listing biotech software and obscure AI wrapper names as watchlist candidates without explicit positions.
LOW
03:58
Aug 28
Aug 28
Author frames biotech software as his biggest AI bet but lists it as a speculative watchlist.
Author frames biotech software as his biggest AI bet but lists it as a speculative watchlist without explicit position markers or price targets.
LOW
20:05
Aug 27
Aug 27
Moderna announces FDA approval for its updated 2026-2027 COVID-19 vaccines.
Moderna announces FDA approval for its updated 2026-2027 COVID-19 vaccines, including MNEXSPIKE and Spikevax formulations.
16:05
Aug 27
Aug 27
Moderna plans to raise two billion dollars through convertible debt to fund its cancer vaccine.
Moderna plans to raise two billion dollars through convertible debt to fund its cancer vaccine business and repay existing debt.
13:34
Aug 27
Aug 27
The author dismisses the breakeven thesis for MRNA, noting delta hedges dominate.
The author dismisses the breakeven thesis for MRNA, noting delta hedges dominate, but offers no explicit position or directional call.
12:29
Aug 27
Aug 27
MRNA monetizes volatility, not value
Speaker says MRNA is monetizing stock volatility because it cannot monetize value; no explicit directional call.
LOW
12:22
Aug 27
Aug 27
MRNA convert deal and first-half loss
Notes MRNA's $2B convertible deal and $2.1B first-half net loss, without an explicit directional stance.
LOW
12:01
Aug 27
Aug 27
"MRNA $2B convert raise below bear view"
"MRNA raised $2B via convertible notes, less than the speaker expected even while bearish; no explicit directional trade call."
MED
About MRNA Analyst Coverage
Buzzberg tracks MRNA (Moderna Inc.) across 64 sources. 60 bullish vs 13 bearish calls from 98 analysts. Sentiment: predominantly bullish (18%). 267 total trade ideas tracked. Past 7 days: 3 bullish, 9 bearish, 12 watch. Latest voices: seedy19tron, Oh Hyun-jin, Park Se-ik.